Testicular teratoma

Summary

Testicular teratoma (MONDO:0018193) is a disease and 2 clinical trials. Top therapeutic interventions include ipilimumab. A subtype of testicular germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• Clinical trials: 2

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Lifetime Prevalence	<1 / 1 000 000	0.04	Europe	Validated
Point prevalence	<1 / 1 000 000		Europe	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	testicular teratoma
Mondo ID	MONDO:0018193
EFO	EFO:1000573
Orphanet	363483
NCIT	C3877
UMLS	C0238451
MedGen	68669
GARD	0017560
Is cancer (heuristic)	no

Also known as: teratoma of testis · teratoma of the testis · testicular teratoma · testicular teratoma (disease)

Data availability: 1 HPO phenotype · 10 cell lines.

Disease family

This is a subtype of testicular germ cell tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › gonadal germ cell tumor › testicular germ cell tumor › testicular teratoma

Related subtypes (5): testicular pure germ cell tumor, malignant testicular germ cell tumor, childhood testicular germ cell tumor, testicular non-seminomatous germ cell tumor, testicular germ cell tumor 1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00060372	PHASE1	COMPLETED	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
NCT01434355	Not specified	COMPLETED	DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IPILIMUMAB	4	1